Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn:
* About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
Unresectable or metastatic colorectal cancer.
Advanced and/or unresectable biliary tract cancer (BTC)
Hepatocellular carcinoma (HCC) not amenable to locoregional therapy
Locally advanced unresectable or metastatic gastroesophageal cancer
Has a history of (noninfectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or has current ILD or pneumonitis, and/or suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening
Has clinically severe respiratory compromise (based on the investigator's assessment) resulting from intercurrent pulmonary illnesses
Has evidence of any leptomeningeal disease
Has clinically significant corneal disease
Merck Sharp & Dohme LLC
Lead sponsor
Daiichi Sankyo
Collaborator